AstraZeneca Acquires Preclinical Biotech Omniose to Enhance Vaccine Platform
AstraZeneca (AZN) has completed the acquisition of Omniose, a preclinical biotechnology company specializing in polysaccharide conjugate vaccines. While the specific financial terms of the deal were not disclosed, the move aims to bolster AstraZeneca's vaccine development capabilities. Omniose utilizes a unique bioconjugation approach that allows bacterial polysaccharides to be attached to carrier proteins within a single cell. This technology is designed to streamline the production and linking process for next-generation vaccines, potentially improving efficiency in developing treatments against bacterial diseases.
Tickers: $AZN